The fixed combination of fortified vancomycin and amikacin ophthalmic solution-VA solution - In vitro study of the potency and stability

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 台中附設醫院 > 期刊論文 > Item 310903500/30200

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30200

题名:	The fixed combination of fortified vancomycin and amikacin ophthalmic solution-VA solution - In vitro study of the potency and stability
作者:	Lin, JM;Tsai, YY;Fu, YL
贡献者:	附設醫院眼科部;China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan;Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan
日期:	2005
上传时间:	2010-09-24 14:51:00 (UTC+8)
出版者:	LIPPINCOTT WILLIAMS & WILKINS
摘要:	beta-catenin is upregulated in many human cancers and considered to be an oncogene. Hepatocellular carcinoma (HCC) is one of the most prevalent human malignancies, and individuals who are chronic hepatitis B virus (HBV) carriers have a greater than 100-fold increased relative risk of developing HCC. Here we report a mechanism by which HBV-X protein (HBX) upregulates beta-catenin. Erk, which is activated by HBX, associates with GSK-3 beta through a docking Motif ((FKFP)-F-291) of GSK-3 beta and phosphorylates GSK-3 beta at the (43)Thr residue, which primes GSK-3 beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3 beta and upregulation of P-catenin. This pathway is a general signal, as it was also observed in cell lines in which Erk-primed inactivation of GSK-3 beta was regulated by IGF-1, TGF-beta, and receptor tyrosine kinase HER2, and is further supported by immunohistochemical staining in different human tumors, including cancers of the liver, breast, kidney, and stomach.
關聯:	CORNEA 24(6):717-721
显示于类别:	[台中附設醫院] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在CMUR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....